13 Dec 2021 07:00
Byotrol plc ("Byotrol" or the "Company")
Directorate Change
Byotrol plc (AIM: BYOT), the infection prevention technology company, is pleased to announce the appointment of Chris Sedwell as CFO of the Company. Chris joins the Board of Directors with immediate effect.
Nic Hellyer, part-time CFO since May 2019 has now formally left the Company, but will continue to be available to assist in an orderly handover process.
Chris is ACA trained and an ICAEW fellow. He was most recently Portfolio Finance Director of FD & CFO Centre, working with various SMEs to provide finance consultancy. For the preceding six years he was Finance Director of ConvaTec Limited, a FTSE250 listed medical products and technologies business. Prior to this, he was Head of Finance & Administration at Iceland International, a part of the UK supermarket chain Iceland Foods Group.
At the date of this announcement, Mr Sedwell does not have any beneficial interest in the ordinary shares of the Company.
Commenting on the appointment, John Langlands, Chairman of Byotrol plc, said:
"We are very pleased to welcome Chris Sedwell to the Board of Byotrol. He has a wealth of highly relevant industrial and healthcare experience, from listed company to SME. We are convinced that he will be a very important asset to the Company as we continue to grow and develop.
We thank Nic Hellyer for his service to the Company and wish him every success for the future."
Enquiries:
Byotrol Plc | |
John Langlands - Chairman David Traynor - Chief Executive | +44 (0)1925 742 000 |
finnCap (Nominated Adviser and Broker) | +44 (0)20 7220 0500 |
Geoff Nash/Kate Bannatyne - Corporate Finance | |
Richard Chambers - ECM | |
Flagstaff Strategic and Investor Communications | +44 (0)20 7129 1474 |
Tim Thompson/Andrea Seymour/Fergus Mellon
| byotrol@flagstaffcomms.com
|
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
Christopher John Sedwell, aged 45, is, or has been within the last five years, a director or partner in the following companies and partnerships:
Current directorships and partnerships | Previous directorships and partnerships held within the last five years |
Sedwell Consulting Limited | ConvaTec Limited Unomedical Holdings Limited ConvaTec Accessories Limited Unomedical Limited Amcare Limited Alpha-Med (Medical & Surgical) Limited SureCalm Healthcare Limited SureCalm Pharmacy Limited Surecalm Healthcare Holdings Limited B.C.A Direct Limited Resus Positive Limited Akers & Dickinson Limited Novacare UK Limited Unomedical Developments Limited Unoplast (UK) Limited Steriseal Limited Pharma-Plast Limited Farnhurst Medical Limited ConvaTec Speciality Fibres Limited Nottingham Medical Equipment Limited Needle Industries (Sheffield) Limited Lance Blades Limited M.S.B Limited Rotax Razor Company Limited Arthur Wood Limited Allied Medical Services (UK) Limited Bradgate-Unitech Limited Shrimpton & Fletcher Limited |
There are no further disclosures regarding Chris Sedwell pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.